BioTeZ Berlin-Buch GmbH (also including Steffens Biotechnische Analysen GmbH), is a Germany-based manufacturer of reagents and finished tests for the In-Vitro Diagnostics (“IVD”) market, as well as components for the food safety testing market.
BBI Group Chief Executive Officer, Mario Gualano said:
“This latest acquisition of BioTeZ and Steffens-Biotec further enhances our portfolio and positions BBI as a leading immunoassay reagent supplier. It enables us to provide additional products and services in the fight against the COVID pandemic. The combined research and development capability will provide customers of both BioTeZ and BBI with new, innovative products and a broader portfolio for greater choice.
BBI Solutions is a progressive company with ambitious strategies in place. This development is a great achievement, particularly in these unfamiliar and testing times.”
Please follow this link for a copy of the full press release